IRCT20080901001165N40 IRCT 2019-09-06 Bagheiat-allah University of Medical Sciences Evaluation of Therapeutic and safety of clemastine fumarate in symptoms and quality of life in secondry Relapsing MS patients Evaluation of Therapeutic and safety of clemastine fumarate in symptoms and quality of life in secondry Relapsing MS patients 2018-08-01 anticipated 120 Complete https://irct.ir/trial/32708 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Random assignment to intervention and control group, randomize using, random number, Blinding description: The study is done in double bind ways, in which both the researcher and the patient do not know if they received drug or placebo. but it is explained to the patient who is participating in the study and may receive a drug or placebo. 3 Multiple sclerosis. Intervention 1: Intervention group:One milligram pill will take clemastine fumarate every 12 hours for 12 weeks. Intervention 2: Control group:The placebo is taken every 12 hours for 12 weeks. Yes - There is a plan to make this available What will be shared: Some of the information that is not personal is shared. When: Start the access period 6 months after printing the results To whom: University researchers Conditions: Other research is to help with this disease Where to obtain: zamanitayyebe@gmail.com How to obtain: After sending the email up to two weeks Comments: